Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma (NASDAQ: STRO) is a clinical-stage biopharmaceutical company pioneering next-generation oncology therapeutics through its proprietary cell-free XpressCF® platform. This page provides centralized access to official news, including clinical trial updates, strategic partnerships, and financial developments.
Investors and researchers will find timely updates on the company’s innovative antibody drug conjugates (ADCs) and bispecific antibody programs. Content categories include clinical milestones, regulatory filings, collaboration announcements, and manufacturing advancements.
Bookmark this page to stay informed about Sutro’s progress in developing precision oncology treatments and its role in advancing cell-free therapeutic innovation. Check regularly for verified updates directly from the company and trusted sources.
Rhea-AI Summary
Sutro Biopharma, Inc. reported its financial results for 2023, showcasing a strong cash position of $333.7 million and key advancements in its luvelta ADC franchise, with promising data in pediatric leukemia patients. The company plans to initiate multiple trials in 2024 and expand its pipeline with new ADCs, securing collaborations for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.83%
Tags
-
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) CEO Bill Newell to participate in three upcoming investor conferences to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, TD Cowen 44th Annual Health Care Conference, and Barclays 26th Annual Global Healthcare Conference. Webcasts of the presentations will be accessible through the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
-
News
Rhea-AI Summary
Sutro Biopharma, Inc. (NASDAQ: STRO) presents promising data on luvelta, a novel folate receptor-α (FolRα) targeting ADC, supporting a registration-enabling trial for platinum-resistant ovarian cancer. The potential benefit to 8 out of 10 patients with low-medium FolRα expression addresses an unmet need in the market. The company highlights luvelta's clinical activity and tolerability as a monotherapy and in combination across multiple cancers, presenting a significant commercial opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.4%
Tags
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) announces investor webcast to highlight clinical activity of Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC, in multiple tumor types. The company is enrolling patients in a Phase 2/3 study for platinum-resistant ovarian cancer and will discuss the potential for luvelta in a range of additional FolRα expressing cancers. The webcast will feature presentations by senior management and external key opinion leaders in oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
-
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) announced positive data on the anti-leukemic activity of luvelta in pediatric patients with CBF/GLIS AML. 42% of patients with ≥5% blasts achieved complete remission, and 75% of pediatric patients with <5% blasts achieved complete remission. Luvelta was well-tolerated and supported potential further development in CBF/GLIS AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
-
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) CEO, Bill Newell, to participate in virtual fireside chat at JMP Securities Hematology and Oncology Summit on December 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) promotes Jane Chung to President and Chief Operating Officer, effective December 1, 2023. She will drive operational excellence, strategic growth, and overall business success, leading cross-functional activities to guide company-wide strategic alignment and value creation across Sutro's R&D pipeline, product portfolio, therapeutic areas of focus, and commercial strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
-
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) reported positive financial results for Q3 2023, with $321.1 million in cash and investments. The company presented encouraging data for luvelta in endometrial cancer and announced Dr. Hans-Peter Gerber as the new CSO. The upcoming ASH 2023 will feature updated data on luvelta's anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
-
Rhea-AI Summary
Sutro Biopharma announces encouraging preliminary results from a Phase 1 study of luvelta in endometrial cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Sutro Biopharma to present at the 14th Annual World ADC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
Sutro Biopharma
Nasdaq:STRO
STRO Rankings
STRO Stock Data
43.95M
80.08M
4.21%
73.99%
5.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO